

## CURRICULUM VITAE

**Name: MARILYN EMILY MORRIS**

**Personal Data:**

Business address: 527 Hochstetter Hall  
Department of Pharmaceutical Sciences  
School of Pharmacy  
University at Buffalo  
State University of New York  
Amherst, New York 14260  
(716) 645-2842 ext.230 Fax (716) 645-3693  
e-mail: memorris@buffalo.edu

**Education:**

1984-1985 Post-doctoral Fellowship  
University of Toronto, Toronto, Ontario, Canada  
Advisor: Dr. \_\_\_\_\_

1978-1984 Ph.D. (Pharmaceutics)  
State University of New York at Buffalo, Amherst, NY  
Thesis: Pharmacokinetic Studies of the Conjugation of Drugs with Sulfate.  
Advisor: Dr \_\_\_\_\_

1974-1976 M.Sc. (Pharmacology)  
University of Ottawa, Ottawa, Ontario, Canada  
Thesis: Analgesic Activity of Floctafenine in Post-Cholecystectomy Patients  
Advisor: Dr. \_\_\_\_\_

1973-1974 Hospital Pharmacy Residency Program, Ottawa General Hospital  
Ottawa, Ontario

1969-1973 B.Sc. (Pharmacy)  
University of Manitoba, Winnipeg, Manitoba, Canada

**Honors/ Awards:**

2005 Faculty in Leadership Fellow, University at Buffalo  
2005 Francis Dudley Meyer Award for Breast Cancer Research, Cancer Research and Prevention Foundation  
2003 Fellow, American Association of Pharmaceutical Scientists  
1999 National Science Foundation POWRE Award  
1996 National Science Foundation Career Development Award  
1990 Dr. Nuala McGann Drescher Award, State University of New York  
1986 Merck Faculty Development Award

1984-1985	Medical Research Council of Canada Fellowship
1983	Buffalo Pharmaceuticals Graduate Scholar (first recipient of award)
1978-1982	Graduate School Fellowship, State University of New York at Buffalo
1974	Canadian Foundation for the Advancement of Pharmacy Scholarship
1974-1975	Medical Research Council of Canada Studentship
1973	University Gold Medal in Pharmacy, University of Manitoba (highest standing in graduating class)
1973	Manitoba Pharmaceutical Association Silver Medal
1972	Centennial Scholar, Faculty of Pharmacy, University of Manitoba (outstanding third year student)

### **Research and Professional Experience:**

2006-present	Associate Dean, Graduate School, University at Buffalo, State University of New York, Amherst NY
2001-present	Professor, Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, State University of New York, Amherst NY
1994-95	Sabbatical Leave: Dr. _____, Department of Biological Sciences, SUNY/Buffalo and Dr. _____, Institute of Physiology, University of Zurich
1992-2001	Associate Professor, Department of Pharmaceutics, School of Pharmacy, University at Buffalo, State University of New York, Amherst NY
1985-1991	Assistant Professor, Department of Pharmaceutics, School of Pharmacy, University at Buffalo, State University of New York, Amherst NY
1984-1985	Post-doctoral Fellow, Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada.
1978-1984	Graduate Research Assistant, Department of Pharmaceutics, School of Pharmacy, State University of New York at Buffalo, Amherst, NY.
1977-1978	Assistant Professor, College of Pharmacy, Dalhousie University, Halifax, Nova Scotia, Canada.
1976-1977	Lecturer, College of Pharmacy, Dalhousie University, Halifax, Nova Scotia, Canada.
1975-1976	Staff Pharmacist, Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada.
1974-1975	Graduate Research Assistant, Department of Pharmacology, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada

### **Publications**

#### **Papers:**

1. Morris ME and Henderson IWD: Analgesic activity of floctafenine after cholecystectomy, Clin Pharmacol Ther 23:383-389, 1978.

2. Morris ME: Compatibility and stability of diazepam injection following dilution with intravenous fluids, *Am J Hosp Pharm* 35:669-672, 1978.
3. Morris ME: Intravenous drug incompatibilities, *Am J Nurs* 79:1288-1292, 1979.
4. Parker WA, Morris ME and Shearer CA: Incompatibility of diazepam injection in plastic intravenous bags, *Am J Hosp Pharm* 36:505-507, 1979.
5. Parker WA, Morris ME and Shearer CA: Oral contraceptive-induced ischemic bowel disease, *Am J Hosp Pharm* 36:1103-1106, 1979.
6. Morris ME and Parker WA: Compatibility of chlordiazepoxide HCl injection following dilution, *Can J Pharm Sci* 16:43-45, 1981.
7. Morris ME and Levy G: Serum concentration and renal excretion by normal adults of inorganic sulfate after acetaminophen, ascorbic acid or sodium sulfate, *Clin Pharmacol Ther* 33:529-536, 1983.
8. Morris ME and Levy G: Determination of salicylamide and five metabolites in biologic fluids by high performance liquid chromatography, *J Pharm Sci* 72:612-617, 1983.
9. Morris ME and Levy G: Plasma inorganic sulfate concentrations in pregnant women, *J Pharm Sci* 72:715-716, 1983.
10. Morris ME and Levy G: Absorption of sulfate from orally administered magnesium sulfate in man, *J Toxicol* 20:107-114, 1983.
11. Morris ME and Levy G: Renal clearance and serum protein binding of acetaminophen and its conjugates in normal adults, *J Pharm Sci* 73:1038-1041, 1984.
12. Morris ME, Galinsky RE and Levy G: Depletion of endogenous inorganic sulfate in the mammalian central nervous system by acetaminophen, *J Pharm Sci* 73:853, 1984.
13. Morris ME and Levy G: Pharmacodynamics of the hypnotic effect of salicylamide in rats, *J Pharm Sci* 74:599-602, 1985.
14. Morris ME, Gengo FM, Kinkel WR, Castellani DA and Levy G: Effect of acetaminophen on inorganic sulfate concentrations in human cerebrospinal fluid, *J Pharm Sci* 75:722-723, 1986.
15. Morris ME and Pang KS: The competition between two enzymes for substrate removal in liver: Modulating effects due to substrate recruitment of hepatocyte activity, *J Pharmacokin Biopharm* 15:473-496, 1987.
16. Morris ME, LeRoy S and Sutton SC: Absorption of magnesium from orally administered magnesium sulfate in man, *J Toxicol (Clin Toxicol)* 25:371-382, 1987.
17. Morris ME, Yuen V, Tang BK and Pang KS: Competing pathways in drug metabolism. I. Effect of input concentration on the conjugation of gentisamide in the once-through *in situ* perfused rat liver preparation, *J Pharmacol Exp Ther* 245:614-624, 1988.
18. Morris ME, Kwon O and Mansfield IL: Sulfate Homeostasis I. The effect of salicylic acid and its metabolites on inorganic sulfate in rats, *J Pharmacol Exp Ther* 244:945-949, 1988.

19. Morris ME, Yuen V and Pang KS: Competing pathways in drug metabolism. II. Enzymic systems for 2-and 5-sulfoconjugation are distributed anterior to 5-glucuronidation in the metabolism of gentisamide by the perfused rat liver, *J Pharmacokin Biopharm* 16:633-656, 1988.
20. Morris ME and Levy G: Assay of inorganic sulfate in biologic fluids by nonsuppressed (single-column) ion chromatography, *Anal Biochem* 172:16-21, 1988.
21. Morris ME and Mansfield IL: Effect of an analgesic dose of aspirin on electrolyte disposition in humans, *J Pharm Sci*, 14:814-815, 1988.
22. Morris ME, Griener JC and Msall ME: N-Acetylator variability in Down's Syndrome: Characterization with caffeine, *Clin Pharmacol Ther* 46:359-366, 1989.
23. Morris ME and Benincosa LJ: Sulfate homeostasis II. Influence of chronic aspirin administration on inorganic sulfate in humans, *Pharm Res* 7:719-722, 1990.
24. Morris ME and Darling IM: Magnesium CSF concentrations and protein binding in magnesium-deficient rats, *J Pharm Sci*, 79:458-459, 1990.
25. Morris ME: Pharmacokinetics of salicylic acid and salicyl phenolic glucuronide in rats, *Drug Metab Disp*, 18:809-811, 1990.
26. Morris ME and Hansel SB: HPLC assay of p-nitrophenol and its conjugates in biological fluids, *J Chromatogr*, 532:285-293, 1990.
27. Darling IM and Morris ME: Evaluation of "true" creatinine clearance in rats reveals extensive renal secretion, *Pharm Res* 8:1318-1322, 1991.
28. Morris ME, Freer JP and Watson WA: Sulfate Homeostasis III. Effect of chronic naproxen or sulindac treatment on inorganic sulfate disposition in arthritic patients with renal impairment, *Pharm Res* 8:242-246, 1991.
29. Darling IM and Morris ME: Sulfate homeostasis IV. Probenecid-induced alterations in inorganic sulfate clearance in rats, *Pharm Res* 8:376-379, 1991.
30. Morris ME and Benincosa LJ: Influence of NSAID-induced inhibition of renal prostaglandin synthesis on inorganic sulfate disposition in rats, *Proc Soc Exp Biol Med* 199:410-416, 1992.
31. Morris ME: Brain and CSF magnesium concentrations during magnesium deficit in animals and humans, *Magnesium Res* 5:303-313, 1993.
32. Benincosa LJ and Morris ME: Influence of dibutyryl-cAMP on ibuprofen-induced alterations of sulfate renal clearance in rats, *Drug Metab Disp* 20:461-464, 1992.
33. Brazeau GA and Morris ME: On the tenure clock. *J Pharm Educ*, 56:320, 1992.
34. Benincosa LJ and Morris ME: Nonlinear pharmacokinetics and protein binding of tiaprofenic acid in female Lewis rats, *J Pharm Sci* 82:429-430, 1993.
35. Benincosa LJ and Morris ME: Tiaprofenic acid inhibits the renal reabsorption of sulfate in rats, *Prost Leuk Essent Fatty Acids* 49:503-508, 1993.

36. Benincosa LJ and Morris ME: Inhibition of sulfate transport in rat kidney membrane vesicle preparations by nonsteroidal antiinflammatory drugs. *Drug Metab Disp* 21:750-752, 1993.
37. Darling IM, Chen Q, Mammerella ML and Morris ME: Salicylate inhibits the renal transport of inorganic sulfate in rat renal membrane vesicles, *Drug Metab Disp* 22:318-323, 1994.
38. Benincosa LJ, Sagawa K and Morris ME: Renal adaptation to altered dietary sulfate in rats, *J Pharmacol Exp Ther* 272:248-255, 1995.
39. Zmlauski-Tucker MJ, Morris ME and Springate JE: Ifosfamide metabolite chloroacetaldehyde causes Fanconi Syndrome in the perfused rat kidney, *Toxicol Appl Pharmacol* 129:170-175, 1994.
40. Kwon Y and Morris ME: Hepatic membrane transport of organic cations using isolated rat hepatocyte membrane vesicles: structure-transport relationships. *Pharm Res* 12:1109-1114, 1995.
41. Benincosa LJ, Sagawa K, Massey LK and Morris ME: Effects of caffeine ingestion and menopause on sulfate homeostasis in women. *Life Sci* 57:1497-1505, 1995.
42. Kwon Y, Lee RD and Morris ME: Hepatic uptake of choline in rat liver basolateral and canalicular membrane vesicle preparations. *J Pharmacol Exp Ther* 279:774-781, 1996.
43. Hansel SD and Morris ME: Hepatic conjugation/deconjugation cycling pathways. Computer simulations examining the effect of Michaelis-Menten parameters, enzyme distribution patterns and a diffusional barrier on metabolite disposition, *J Pharmacokin Biopharm* 24:219-243, 1996.
44. Kwon Y, Kamath AV and Morris ME: Inhibitors of p-glycoprotein-mediated daunomycin transport in rat liver canalicular membrane vesicles, *J Pharm Sci* 85:935-939, 1996.
45. Kwon Y and Morris ME: Membrane transport in hepatic clearance of drugs. I. Extended hepatic clearance models incorporating concentration-dependent transport and elimination processes, *Pharm Res* 14:774-779, 1997.
46. Kwon Y and Morris ME: Membrane transport in hepatic clearance of drugs. II. Zonal distribution patterns of concentration-dependent transport and elimination processes, *Pharm Res* 14: 780-785, 1997.
47. Balasubramanian SV, Straubinger RM and Morris ME: Salicylic acid induces changes in the physical properties of model and native membranes, *J Pharm Sci* 86:199-204, 1997.
48. Kamath AV and Morris ME: Functional expression of P-glycoprotein in the hepatic canalicular membrane of developing rats, *J Pharm Sci* 87:300-305, 1998.
49. Sagawa, K, DuBois DC, Almon RR, Han B, Biber J, Murer H and Morris ME: Detection and quantitation of sodium-dependent sulfate cotransport (NaSi-1) by sandwich type enzyme-linked immunosorbent assay. *Pflugers Arch Eur J Physiol* 437:123-129, 1998.
50. Sagawa K and Morris ME: Cellular mechanisms of renal adaptation of sodium-dependent sulfate cotransport to altered dietary sulfate in rats. *J Pharmacol Exp Ther* 287:1056-1062, 1998.

51. Sagawa K, Benincosa LJ, Murer H and Morris ME: Ibuprofen-induced changes in sulfate renal transport, *J Pharmacol Exp Ther* 287:1092-1097, 1998.
52. Sagawa K, Murer H and Morris ME: Effect of experimentally induced hypothyroidism on sulfate renal transport in rats. *Am J Physiol* 276:F164-F171, 1999.
53. Lee H-J, Balasubramanian SV and Morris ME: Effect of pregnancy, postnatal growth and gender on renal sulfate transport, *Proc Soc Exp Biol Med* 221:336-344, 1999.
54. Sagawa K, Han B, DuBois DC, Murer H, Almon RR, Morris ME: Age and growth hormone induced alterations in renal sulfate transport, *J Pharmacol Exp Ther* 290:1182-1187, 1999.
55. Lee H-J, Balasubramanian SV, Murer H, Biber J and Morris ME: Modulation of sulfate renal transport by alterations in cell membrane fluidity, *J Pharm Sci* 88:976-980, 1999.
56. Morris ME and Sagawa K: Molecular mechanisms of renal sulfate homeostasis, *Crit Rev Clin Lab Sci*, 37:345-388, 2000.
57. Parikh HH, Balasubramanian V, Chui WL, Morris ME, Ramanathan M: Rapid solubility determination using phase osmometry. *J Biomolec Screening* 4:315-318, 1999.
58. Lee H-J, Sagawa K, Murer H, Morris ME: Hormonal regulation of sodium/sulfate cotransport in renal epithelial cells, *Proc Soc Exp Biol Med*, 225:49-57, 2000.
59. Parikh HH, McElwain K, Balasubramanian V, Leung W, Wong D, Morris ME, Ramanathan M. A rapid spectrofluorimetric technique for determining drug-serum protein binding suitable for high-throughput screening. *Pharm Res* 17:632-637, 2000.
60. Sagawa, K, Darling IM, Murer H, Morris ME. Glucocorticoid-induced alterations of renal sulfate transport. *J Pharmacol Exp Ther* 294:658-663, 2000.
61. Morris ME, Murer H. Molecular mechanisms in renal and intestinal sulfate (re)absorption. *J Memb Biol*, 181:1-9, 2001.
62. Tseng E, Kamath AV, Zhang S and Morris ME. Effect of organic isothiocyanates on the P-glycoprotein and MRP1-mediated transport of daunomycin and vinblastine, *Pharm Res* 19:1509-1515, 2002.
63. Nguyen H, Zhang S, Morris ME. Effect of flavonoids on MRP1-mediated transport in Panc1 cells, *J Pharm Sci* 92:250-257, 2003
64. Morris ME, Lee H-J, Predko LM. Gender differences in the membrane transport of endogenous and exogenous compounds, *Pharmacol Rev* 55:229-240, 2003.
65. Hu K and Morris ME: Determination of 1-naphthylisothiocyanate (1-NITC) and metabolites 1-naphthylamine (1-NA) and 1-naphthylisocyanate (1-NIC) in rat plasma and urine by high-performance liquid chromatography, *J Chromatography B* 788:17-28,2003.
66. Zhang S and Morris ME: Effects of the Flavonoids Biochanin A, Morin, Phloretin and Silymarin on P-glycoprotein-Mediated Transport, *J Pharmacol Exp Ther* 304:1258-1267, 2003.

67. Zhang S, Morris ME: Effect of flavonoids biochanin A and silymarin on the P-glycoprotein-mediated transport of digoxin and vinblastine in human intestinal Caco-2 cells, *Pharm Res* 20:1184-1191, 2003.
68. Kamath AV, Darling IM and Morris ME: Choline uptake in human intestinal Caco-2 cells is carrier-mediated. *J Nutr* 133:2607-2611, 2003.
69. Ji Y and Morris ME: Determination of phenethyl isothiocyanate in human plasma and urine by ammonia derivatization and liquid chromatography-tandem mass spectrometry. *Anal Biochem*, 323:39-47, 2003.
70. Zhang S and Morris ME: Efflux transporters in drug excretion. In *Drug Delivery: Principles and Applications*. Wang B (editor), John Wiley & Sons Inc., 2005, pp. 381-409.
71. Moon YJ, Wang X and Morris ME: Dietary flavonoids: Effects on xenobiotic and carcinogen metabolism, *Toxicology In Vitro* 20(2):187-210, 2006
72. Zhang S, Yang X, Morris ME. Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport, *Mol Pharmacol* 65:1208-1216, 2004.
73. Tseng E, Scott-Ramsay EA, Morris ME. Dietary organic isothiocyanates are cytotoxic in the human breast cancer MCF-7 and mammary epithelial 12-A cell lines, *Exp Biol Med*, 229(8):835-42, 2004.
74. Hu K and Morris ME: Effects of benzyl-, phenethyl- and  $\alpha$ -naphthyl isothiocyanates on P-glycoprotein and MRP1-mediated transport, *J Pharm Sci*, 93: 1901-1911, 2004.
75. Zhang S, Yang X and Morris ME: Combined effects of multiple flavonoids on breast cancer resistance protein (ABCG2)-mediated transport. *Pharm Res*, 21:1263-1273, 2004.
76. Ji Y and Morris ME. Effect of organic isothiocyanates on breast cancer resistance protein (ABCG2)-mediated transport, *Pharm Res* 21(12):2261-2269, 2004.
77. Zhang S, Wang X, Sagawa K, Morris ME. Flavonoids chrysin and benzoflavone, potent BCRP inhibitors, have no significant effect on topotecan pharmacokinetics in rats or *mdr1a/1b*(-/-) mice, *Drug Metab Disp* 33(3):341-8, 2005.
78. Zhou XF, Zhang L, Tseng E, Scott-Ramsay EA, Schentag JJ, Coburn RA, Morris ME. New 4-aryl-1,4-dihydropyridines and 4-arylpyridines as P-glycoprotein inhibitors, *Drug Metab Disp* 33(3):321-328, 2005.
79. Morris ME and Telang U. Isothiocyanates and Cancer Prevention. In *Nutrition and Cancer Prevention*, Awad AB and Bradford PG (editors), Marcel Dekker Inc, 2005.
80. Morris ME and Zhang S. Flavonoid-Drug Interactions: Effects of flavonoids on ABC transporters. *Life Sci* 2006 Jan 30; [Epub ahead of print].
81. Morris ME, Hu K and Wang Q. Renal Clearance of  $\gamma$ -Hydroxybutyric Acid in Rats: Increasing Renal Elimination as a Detoxification Strategy. *J Pharmacol Exp Ther*. 313:1194-1202, 2005.

82. Zhou XF, Wang Q, Coburn RA and Morris ME. A high-performance liquid chromatographic method for determination of the niguldipine analogue DHP-014. *Biomed Chromatogr* 20:48-53, 2006.
83. Wang L and Morris ME. Liquid Chromatography-Tandem Mass Spectroscopy Assay for Quercetin and Conjugated Quercetin Metabolites in Human Plasma and Urine. *J Chromatogr* 821:194-201, 2005.
84. Zhang S, Yang X, Coburn RA and Morris ME. Structure activity relationships and quantitative structure activity relationships for the flavonoid-mediated inhibition of breast cancer resistance protein. *Biochem Pharmacol* 70:627-639, 2005.
85. Zhou XF, Coburn RA and Morris ME. Effects of new 4-aryl-1,4-dihydropyridines and 4-arylpiperidines on drug efflux mediated by multidrug resistance-associated protein-1. *J Pharm Sci.* 94(10):2256-65, 2005.
86. Zhou XF, MacDiarmid, Coburn RA and Morris ME. Pharmacokinetics and bioavailability of a newly synthesized dihydropyridine compound with multidrug reversal activity. *Biopharm Drug Dispos* 26:279-285, 2005.
87. Zhou XF, Yang X, Wang Q, Coburn RA and Morris ME. Effects of dihydropyridines and piperidines on multidrug resistance mediated by breast cancer resistance protein:in vitro and in vivo studies. *Drug Metab Disp* 33(8):1220-8, 2005.
88. Hu K and Morris ME. Pharmacokinetics of  $\alpha$ -naphthyl isothiocyanate in rats. *J Pharm Sci* 94(11):2441-51, 2005.
89. Ji Y, Kuo Y and Morris ME. Pharmacokinetics of dietary phenethyl isothiocyanate in rats, *Pharm Res* 22(10):1658-66, 2005.
90. Ji Y and Morris ME. Transport of dietary phenethyl isothiocyanate is mediated by multidrug resistance protein 2 but not P-glycoprotein, *Biochem Pharmacol* 70:640-647, 2005.
91. Ji Y and Morris ME. Membrane Transport of Dietary Phenethyl Isothiocyanate by Breast Cancer Resistance Protein (ABCG2), *Molecular Pharmaceutics* 2(5):414-9, 2005.
92. Zhou XF, Shao Q, Coburn RA and Morris ME. Quantitative Structure-Activity Relationship and Quantitative Structure-Pharmacokinetics Relationship of 1,4-Dihydropyridines and Piperidines as Multidrug Resistance Modulators, *Pharm Res.* 22(12): 1989-1996, 2005.
93. Wang X, Wolkoff AW, and Morris ME. Flavonoids as a novel class of human organic anion transporting polypeptide OATP1B1 (OATP-C) modulators. *Drug Metab Disp*, 33(11):1666-72, 2005.
94. Moon Y, Brazeau DA and Morris ME. Effects of Flavonoids Genistein and Biochanin A on Gene Expression and Their Metabolism in Human Mammary Cells, submitted.
95. Moon YJ, Sagawa K, Frederick K, Zhang S, and Morris ME. Pharmacokinetics and Bioavailability of the Isoflavone Biochanin A in Rats, *AAPS Journal*,.



96. DiCenzo R, Larpanichpoonphol P, Predko P, Chen A, Frerichs V, Reichman R, Morris ME. Effects of quercetin on saquinavir plasma and intracellular concentrations in healthy adults, accepted.
97. Morris ME. ABCG2 New evidence of the importance of this ABC transporter in drug disposition, AAPS Newsmagazine p. 20-21, September 2005.
98. Wang Q, Lu Y, Yuan M, Darling IM, Repasky EA, Morris ME. Characterization of monocarboxylate transport in human kidney HK-2 cells, Mol Pharmaceut, submitted.
99. Wang Q, Darling IM and Morris ME. Transport of gamma-hydroxybutyrate in rat kidney membrane vesicles- Role of monocarboxylate transporters, J Pharmacol Exp Ther, Epub 2006.
100. Moon YJ, Zhang S, Brazeau DA and Morris ME. Effects of biochanin A on gene expression in primary human hepatocytes, submitted.

**Books:**

1. Morris ME: Intravenous Drug Therapy, Ottawa General Hospital, Ottawa, Ontario, 1978.
2. \_\_\_\_\_, in preparation, to be published 2006.

**Conference Proceedings:**

1. Morris ME: The role of dietary sulphate in drug metabolism. Symposium on Sulphur Nutrition and Metabolism, Canadian Federation of Biological Sciences, 29:44, 1986.
2. Pang KS, Xu X, Morris ME and Yuen V: Kinetic modeling of conjugation reactions in the liver, Fed Proc 46:2439-2441, 1987.
3. Morris ME: Hepatic Metabolism in "Biological Data for Pharmacokinetic Modeling and Risk Assessment", United States Environmental Protection Agency, Washington, D.C., 1989, pp. B20-B23.
4. Morris ME: Predicting hepatic clearance of xenobiotics from in vitro data, Novel Strategies for Accelerated ADME/Toxicity Screening. NMHCC Conference Proceedings, 1997.
5. Morris ME: Effects of High Sulfate Exposures in Health Effects from Exposure to Sulfate in Drinking Water Workshop, United States Environmental Protection Agency. Report published, January, 1999.

**Patents**

2002 Patent " High Throughput Spectrofluorimetric Screen for Drug Binding to Human Serum Proteins" Murali Ramanathan, Marilyn E. Morris

**Administrative Responsibilities/Service:**

**University**

1987-88	Ad hoc University Health Sciences Library Committee
1990-94	Member, Institutional Animal Care and Use Committee (IACUC)
1992-93	Chair, Subcommittee A (Protocol review), IACUC; Vice Chair, IACUC
1993-94	Chair, University Laboratory Animal Care Committee
1994-95	Chair, Subcommittee B, University Laboratory Animal Care Committee
1996-01	Member, Health Sciences Divisional Committee (HSDC)
1996-99	Chair, HSDC
1996-present	Judge, Sigma Xi Annual Research Competition, SUNY/Buffalo
1996-98	[ ]
1997-98	Member, Search Committee for School of Pharmacy Dean.
1999-00	Chair, Subcommittee on New Graduate Courses, HSDC
1996-99	Member, Graduate School Executive Committee
1997- present	Member of Steering Committee, Institute for Research and Education on Women and Gender (IREWG)
1997-2003	Member, Research Committee, IREWG
1997-2003	Member, Education Committee, IREWG
2001-2003	Member, Middle States Accreditation Committee on Faculty
2002-present	Member, Furnas Athlete-Scholar Award Committee
2002-2005	Member, Steering Committee for MD-PhD program
2005	Committee Member, Search Committee for Director of University Laboratory Facilities
2005-present	University at Buffalo, SUNY Honorary Degree Committee
2005-present	Dreyfus Teacher-Scholar Award Committee
2005-2006	Faculty in Leadership Program

### School of Pharmacy

1988-92	Member, Undergraduate Admissions Committee
1990-91	AACP Delegate for the School of Pharmacy
1992-94	Member, Curriculum Committee (for Pharm.D. curriculum)
1992-93	Member, Curriculum Committee (for second professional year) for Pharm.D. Program
1993-94	Member, Search Committee for Chair of Pharmacy Practice
1998-99	Member, School of Pharmacy Accreditation Committee
1999-01	American Association of Colleges of Pharmacy (AACP), Graduate and Research Liaison
2000-present	_____
2002-2003	Chair, Dean Review Committee
2004-present	Member, Curriculum Committee
2005	Member, Pharm.D. Admissions Committee
2005	Member, School of Pharmacy Accreditation Committee

### Department of Pharmaceutical Sciences

many years	Buffalo Pharmaceutics Graduate Student Award Committee
1993- 2001	Director, Graduate Studies, Dept. of Pharmaceutical sciences
1993- present	Graduate Affairs Committee, Dept. of Pharmaceutical Sciences
2000-01	Co-Chair, Search Committee for Department Chair

**National Committees**

1990-91	American Assoc. of Pharmaceutical Scientists (AAPS) Subcommittee on New Academic Programs.
1990-92	AAPS - Organizational Committee for the Women's Forum
1992, 1998	Expert Panel Committee member for the Environmental Protection Agency.
1992	Moderator and organizer of symposium on "Hiring and Retention of Pharmaceutical Scientists" at AAPS Annual Meeting
1992-93	Member, Graduate Education Committee for Pharmacokinetics, Pharmacodynamics and Drug Metabolism (PPDM) Section for AAPS.
1993-94	Chair of Graduate Education Committee for PPDM Section for AAPS
1993	Committee Member, Meritorious Manuscript Committee, PPDM Section, AAPS.
1994	Participant in Fireside Chats "Research Ethics", AAPS Annual Meeting
1996-present	Abstract reviewer for PPDM Section of AAPS
2000	Committee Member. AAPS PPDM section for Travel Awards (set up award and evaluated applications)
2000	Committee Member, AAPS Research Achievement Award
2001-2003	Chair, PPDM Section, Awards Committee and Member, AAPS Awards Committee
2001-2003	Executive Committee-Transport Focus Group, AAPS
2001-03	Women's Committee, ASPET
2003-2005	Secretary/Treasurer, Pharmacokinetics, Pharmacodynamics and Drug Metabolism Section, American Assoc. of Pharmaceutical Scientists
2005-2009	President-elect, Pharmacokinetics, Pharmacodynamics and Drug Metabolism Section, American Assoc. of Pharmaceutical Scientists
2004-2005	Faculty delegate, American Assoc. of Colleges of Pharmacy
2004-2005	Member, American Federation for Pharmacy Accreditation Science Curriculum Comm., American Assoc. of Colleges of Pharmacy.

**Journal Editorial Boards**

1999- 2001	Associate Editor, Pharmacological Reviews
1998- present	Editorial Board, AAPS Journal
1995- present	Editorial Board, Journal of Pharmaceutical Science
2005- present	Editorial Board, Pharmaceutical Research

Reviewer for many other journals including Drug Metabolism and Disposition, Journal of Pharmacology and Experimental Therapeutics, Pharmaceutical Research, International Journal of Pharmaceutics, American Journal of Physiology, Journal of Biopharmaceutics Pharmacokinetics, Journal of Clinical Investigation, Current Topics in Peptide Delivery, ACS Books

**Grant Reviewer**

Susan G. Komen Breast Cancer Foundation (1999, 2000, 2001, 2002, 2003, 2004)  
National Science Foundation, IBN Study Section (2001)  
University of Michigan Upjohn Grant Program (2000)  
United University Professionals, SUNY/Buffalo Grant Program (2000, 2001, 2002, 2003)  
NIH- ad hoc reviewer for Toxicology Study Section (2000)  
NCI- Special Emphasis Review Panel 2002  
University of Washington Grant Program (2003)  
University at Buffalo, Interdisciplinary Program (2004)  
NIH, Special Emphasis Panel, 2004  
United Kingdom Cancer Program, 2004  
Ohio Cancer Assoc. Grant Program 2005

NIH, Special Emphasis Panel (March, 2005)  
NIH, Special Emphasis Panel (October, 2005)  
NIH, Special Emphasis Panel (February, 2006)

### **Outside Reviewer**

\_\_\_\_\_ Ph.D. dissertation thesis, University of Alberta  
\_\_\_\_\_, Nov 2000 – University of Toronto  
\_\_\_\_\_, Jan 2006- University of Toronto  
\_\_\_\_\_

### **Community Service**

Preceptor for High School and Undergraduate students in research programs for minority students  
AP Biology presentation, Amherst Central High School, May 2005.  
\_\_\_\_\_

### **Minority High School Student Research Apprentice Program**

Summer of 1986 – Preceptor for \_\_\_\_\_  
Summers of 1987 and 1988 – Preceptor for \_\_\_\_\_  
Summers of 1992 and 1993 – Preceptor for \_\_\_\_\_

### **SUNY Alliance for Minority Participation Program (SUNY AMP)**

Summer of 1999 - Preceptor for \_\_\_\_\_

### **Registration and Membership in Professional Societies**

Pharmacy Examining Board of Canada Exams (1973)  
Registered pharmacist in Manitoba and Ontario, Canada  
Member, American Society for Pharmacology and Experimental Therapeutics  
Member, American Association of Pharmaceutical Scientists  
Member, Society for Experimental Biology and Medicine  
Member, United University Professions  
Member, American Association of Colleges of Pharmacy  
Member, International Society for the Study of Xenobiotics  
Member, American Association for Cancer Research

**APPEARS THIS WAY  
ON ORIGINAL**